Form 990 for tax year 2022

Totals

Total revenue

$16,425,940

Total expenses

$11,462,650

Contributions and grants received

$15,386,443

Grants paid

$6,693,567

Program service revenue

$283,846

Investment income

$755,651

Other revenue

$0

Total assets, end of year

$37,659,088

Total liabilities, end of year

$14,828,822

Net assets or fund balances, end of year

$22,830,266

Program services expenses (Part IX)

$9,133,098

Management and general expenses

$981,587

Fundraising expenses

$1,347,965

Program service expenses (Part III)

$9,133,098

Program services were 79.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2022

• OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES. OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. EACH YEAR THERE WILL BE OVER 19,000 NEW CASES OF OVARIAN CANCER IN THE UNITED STATES, AND APPROXIMATELY 14,000 WOMEN WILL DIE OF THE DISEASE. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN CANCER COMMUNITY. SINCE 1998, OCRA HAS AWARDED 398 GRANTS FOR OVARIAN CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 93 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $113 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION, AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN CANCER AND DETERMINING THE ORIGINS OF THE DISEASE, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, AND ENHANCE PATIENTS' QUALITY OF LIFE. FINALLY, THEY ARE DECIPHERING HOW AND WHY OVARIAN CANCER SPREADS, AND HOW TO STOP IT.ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE:SHOWN THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; HELPED EXPLAIN RESISTANCE TO CHEMOTHERAPY; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; EXPLORED THE ROLE OF ESTROGEN IN ANTI-TUMOR IMMUNITY; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; IDENTIFIED A NEW THERAPEUTIC STRATEGY FOR CLEAR CELL OVARIAN CANCER; SHOWN HOW A PARP/IMMUNE THERAPY COMBO SHOWS PROMISE; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; CONFIRMED GENERIC HEART MEDICATION CAN PROLONG SURVIVAL IN OVARIAN CANCER PATIENTS; SHED LIGHT ON HOW OVARIAN CANCER GROWS; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; FOUND THAT A SUBSET OF IMMUNE CELLS PROMOTE TUMOR GROWTH; CLARIFIED WHICH CELL LINES ARE THE BEST FIT FOR USE IN OVARIAN CANCER RESEARCH; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED AREAS OF THE HUMAN GENOME THAT ARE LINKED TO INCREASED RISK FOR OVARIAN CANCER; EVALUATED NEW EXPERIMENTAL MODELS TO ADVANCE OVARIAN CANCER RESEARCH; REVEALED HOW COMBINING TARGETED AGENTS IS EFFECTIVE; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; STUDIED MACROPHAGES TO IMPROVE TREATMENT; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; AND TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER.IN 2022 ALONE, OCRA RESEARCHERS: STUDIED HOW FREQUENT USE OF ASPIRIN IS ASSOCIATED WITH A REDUCTION IN OVARIAN CANCER, USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC, STUDIED HOW KNOCKING OUT KDM5A SHOWED AN INCREASE IN THE PRESENCE AND ACTIVATION OF CD8+ T CELLS, WHICH ARE IMMUNE CELLS THAT KILL CANCER CELLS, DISCOVERED A TOOL TO AID SELECTING THE BEST TREATMENT OPTIONS, DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186), STUDIED HOW PARTNER PROTEINS MAY CONTRIBUTE TO OVARIAN CANCER TUMOR GROWTH, FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL, DISCOVERED GENETIC LINK BETWEEN OVARIAN CANCER SUBTYPES AND ENDOMETRIOSIS, SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK, STUDIED THE BRCA1 GENE MUTATION FOR THE POTENTIAL OF PREDICTING OVARIAN CANCER IN PATIENTS. EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG.

  Expenses $7,195,143 · Grants $6,673,567

• EACH YEAR, OCRA BRINGS TOGETHER OVARIAN CANCER PATIENTS, SURVIVORS AND CAREGIVERS AT THE OVARIAN CANCER NATIONAL CONFERENCE, A THREE DAY-LONG EVENT FILLED WITH INFORMATIONAL SESSIONS FEATURING EXPERT SPEAKERS, FUN AND COMMUNITY. MORE THAN 600 PEOPLE FROM ALL AROUND THE WORLD COME TOGETHER VIRTUALLY FOR THIS EVENT. THE SPIRIT OF UNITY AND HOPE IS ALWAYS STRONG THROUGHOUT THE WEEKEND, WHERE ATTENDEES MEET NEW FRIENDS AND REUNITE WITH OLD ONES, WHILE ATTENDING SESSIONS THAT PROVIDE UP-TO-DATE ANSWERS TO QUESTIONS ABOUT THEIR DIAGNOSIS, TREATMENT, AND SURVIVORSHIP. SESSIONS FEATURE TOP OVARIAN CANCER EXPERTS WHO GENEROUSLY GIVE OF THEIR TIME, PRESENTING THE LATEST IN TREATMENTS, RESEARCH, MANAGING RECURRENCE, GENETICS, NUTRITION, CARETAKER AND SUPPORTER CARE, SUPPORT FOR YOUNG WOMEN, ADVOCACY, AND SO MUCH MORE.

  Expenses $532,402 · Revenue $283,846

• BEYOND OUR CONFERENCE, OCRA HAS ADDITIONAL PATIENT EDUCATION AND SUPPORT PROGRAMS, AND ALSO ENGAGES IN ADVOCACY ON BEHALF OF WOMEN WITH OVARIAN CANCER. OUR WEBSITE IS A COMPREHENSIVE SOURCE OF EDUCATIONAL INFORMATION, AND THROUGHOUT THE COURSE OF THE YEAR WE HOLD A SERIES OF FREE, EDUCATIONAL WEBINARS ON A RANGE OF TOPICS RELATED TO OVARIAN CANCER RESEARCH, TREATMENT, AND SURVIVORSHIP. OCRA'S PATIENT-SUPPORT LINE IS STAFFED BY OUR SOCIAL WORK TEAM DURING BUSINESS HOURS MONDAY THROUGH FRIDAY AND IS AVAILABLE TO ANYONE SEEKING INFORMATION, SUPPORT, PATIENT NAVIGATION, OR RESOURCE REFERRALS (MEDICAL ADVICE IS NOT PROVIDED).OUR WOMAN TO WOMAN PROGRAM IS A PEER-TO-PEER SUPPORT PROGRAM FOR WOMEN WITH GYNECOLOGIC CANCER. OCRA OFFERS BOTH A NATIONAL WOMAN TO WOMAN PROGRAM AND PROVIDES FINANCIAL SUPPORT TO HELP HOSPITALS AND OTHER ORGANIZATIONS START LOCAL WOMAN TO WOMAN PROGRAMS, WHICH ARE NOW AT MORE THAN 35 SITES ACROSS THE COUNTRY. OUR STAYING CONNECTED SUPPORT SERIES, WHICH LAUNCHED IN 2020, NOW OFFERS FOUR WEEKLY GROUPS AND THREE MONTHLY GROUPS WHICH ENABLES ALL IMPACTED BY OVARIAN OR RELATED GYNECOLOGIC CANCERS A WAY TO LEARN, SHARE, AND CONNECT. OUR ARTS PROGRAM, EXPRESS YOURSELF, OFFERS A COMBINATION OF THERAPEUTIC ARTS, POETRY, AND COMMUNITY BUILDING ACTIVITIES. OCRA PARTNERS WITH INSPIRE.COM TO OFFER AN ONLINE SUPPORT COMMUNITY THAT HAS OVER 70,000 MEMBERS WORLD-WIDE. OCRA IS COMMITTED TO ENCOURAGING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS TO FOCUS ON THE CRITICAL NEEDS OF THOSE DIAGNOSED WITH GYNECOLOGIC CANCER, WHETHER BENCH OR BEDSIDE. THOUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT, WE ACCEPT TOP MASTER'S OF SOCIAL WORK CANDIDATES TO TRAIN WITH OUR LICENSED CLINICAL SOCIAL WORKERS TO ADDRESS THE SPECIFIC NEEDS OF OUR COMMUNITY.OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. EACH YEAR, MORE THAN 950 SURVIVOR VOLUNTEERS DELIVERED PRESENTATIONS AT 360+ SCHOOLS IN 38 STATES (AS WELL AS UK, CANADA AND AUSTRALIA), AND REACH OVER 9,500 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS HELP ENSURE THAT THE NEXT GENERATION OF HEALTH CARE PROVIDERS CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS.OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE FOR EVERYONE TOUCHED BY OVARIAN CANCER, AND IS THE VOICE FOR WOMEN WITH OVARIAN CANCER ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES. EACH YEAR OCRA PLAYS A CRITICAL ROLE IN HELPING TO SECURE ABOUT $170 MILLION IN FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION. IN ADDITION, OUR GROWING ADVOCATE LEADER PROGRAM TRAINS MEMBERS OF THE OVARIAN CANCER COMMUNITY TO RAISE AWARENESS THROUGH NEWS ARTICLES AND OUTREACH, DEVELOP RELATIONSHIPS WITH THEIR ELECTED OFFICIALS, AND FIGHT FOR INCREASED FUNDING FOR OVARIAN CANCER RESEARCH THROUGHOUT THE COUNTRY. THROUGH OUR COMMUNITY PARTNERS PROGRAM, OCRA ALSO PLAYS A CRITICAL ROLE UNITING THE COMMUNITY. OCRA'S 80+ COMMUNITY PARTNERS ARE OUTSTANDING GRASSROOTS, LOCAL AND NATIONAL ORGANIZATIONS AROUND THE COUNTRY WHO SHARE A COMMITMENT TO ERADICATE OVARIAN CANCER THROUGH RESEARCH, ADVOCACY, SUPPORT, EDUCATION AND AWARENESS. THE GOAL OF OUR COMMUNITY PARTNERS INITIATIVE IS TO UNITE THE OVARIAN CANCER COMMUNITY INTO A NATIONAL MOVEMENT, SPEAKING WITH ONE VOICE THROUGH INFORMATION SHARING, STRATEGIC INITIATIVES, AND BEST PRACTICES.

  Expenses $1,405,553 · Grants $20,000

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

• MEMORIAL SLOAN-KETTERING CANCER CENTER

  $975,000

  RESEARCH GRANT

• SAN JOSE UNIVERSITY

  $900,000

  RESEARCH GRANT

• HARVARD SCHOOL OF PUBLIC HEALTH

  $900,000

  RESEARCH GRANT

• ST JUDE CHILDREN'S HOSPITAL

  $828,878

  RESEARCH GRANT

• WASHINGTON UNIVERSITY

  $525,000

  RESEARCH GRANT

• ROSWELL PARK CANCER CENTER

  $450,000

  RESEARCH GRANT

• RUTGERS UNIVERSITY

  $450,000

  RESEARCH GRANT

• FRED HUTCHINSON CANCER RESEARCH CENTER

  $450,000

  RESEARCH GRANT

• MAGEE-WOMENS RESEARCH INSTITUTE & FOUNDATION

  $449,093

  RESEARCH GRANT

• STANFORD UNIVERSITY

  $275,000

  RESEARCH GRANT

The 10 largest by cash amount. The API serves every itemized grant.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• OVARIAN CANCER NATIONAL ALLIANCE

  501(C)(3) · EDUCATION & ADVOCACY · DC · controlled entity

  Directly controlled by OVARIAN CANCER RESEARCH FUND INC

Provenance

Return type

form_990

Tax year

2022

Filed

10 November 2023

IRS schema version

2022v5.0

Source object

202323179349311082

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.